Clinical trials: Bronchial Neoplasms
Non Small Cell Lung Cancer, Advanced Cancer
Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer
Lung cancer is one of the most common causes of cancer death worldwide. It is projected that the vast majority, approximately 80% -85% of all lung cancer diagnosis is Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Advanced Cancer, Refractory Cancer
- Trial name
- NCT04840004
- Testing
- PVT-1
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- PlusVitech S.L.
Non-small Cell Lung Cancer
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
The subjects who take part in this clinical research study have advanced non-small cell lung cancer (NSCLC) that has been previously treated with other drugs.
- Trial name
- NCT02730247
- Testing
- ramucirumab, nab-paclitaxel
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Liza Villaruz, MD
Carcinoma, Non-Small-Cell Lung
A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples
EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation…
- Trial name
- NCT01382992
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Non-small Cell Lung Cancer
The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer
The trial evaluates the utility of 18FDG-PET/CT scan in the target definition process when SBRT is planned for stage I NSCLC.
- Trial name
- NCT00380666
- Testing
- PET/CT scan
- Sponsor
- University of Aarhus
Advanced Solid Tumors
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) of OSI-906 in combination with erlotinib
- Trial name
- NCT00739453
- Testing
- OSI-906, erlotinib
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Lung Cancer
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, cisplatin, docetaxel, gemcitabine, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00863512
- Testing
- cisplatin, docetaxel, gemcitabine hydrochloride
- Where
- 94 sites in United States, Australia
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants
RATIONALE: Studying samples of tissue, blood, sputum, and urine from patients with lung cancer and from healthy participants in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers…
- Trial name
- NCT00899028
- Testing
- comparative genomic hybridization, fluorescence in situ hybridization, gene expression analysis
- Where
- 4 sites in United States
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Non-Small Cell Lung Cancer, Brain Neoplasms
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
This was an open-label, multicenter, single-arm, Phase II trial of bevacizumab combined with first- or second-line therapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with previously treated…
- Trial name
- NCT00312728
- Testing
- bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents
- Volunteers
- 115 people
- Sponsor
- Genentech, Inc.
Asthma, COPD
Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease
The aim of the project is to study pathogenetic mechanisms in severe asthma and compare those mechanisms in chronic obstructive pulmonary disease (COPD) in order to test the hypothesis that severe asthma and COPD develop into…
- Trial name
- BIOAIR (NCT00555607)
- Testing
- prednisolone
- Where
- Sweden
- Volunteers
- 233 people
- Sponsor
- Karolinska Institutet
Lung Cancer, Non-small Cell, Artificial Intelligence
Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC
This prospective, single-arm, multicenter, phase II trial enrolled 40 patients who underwent surgery after three cycles of neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin.
- Trial name
- NCT04541251
- Testing
- Camrelizumab + Nab-paclitaxel + Carboplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Small Cell Lung Cancer
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006…
- Trial name
- NCT07559929
- Testing
- DXC006, Toripalimab, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Lung Cancer Early Molecular Assessment Trial
The investigators hypothesize that an early molecular profiling, that includes both tissue and blood-bases analysis, for all NSCLC patients, including stage I-III, will increase diagnostic efficiency.
- Trial name
- LEMA (NCT02894853)
- Testing
- Liquid (blood) biopsies and tumor biopsy (optional)
- Where
- Netherlands
- Volunteers
- 1,297 people
- Sponsor
- The Netherlands Cancer Institute
Lung Cancer, Non-Small Cell
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
The purpose of this clinical trial is to find out how successfully non-small-cell lung cancer patients are able to give an immune response to injections of the immunotherapeutic product GSK1572932A, and to find out more about the…
- Trial name
- NCT00455572
- Testing
- Immunotherapeutic GSK1572932A, Cisplatin (CDDP), Vinorelbine
- Where
- 26 sites in Belgium, Canada and 4 more
- Volunteers
- 71 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer, Liquid Biopsy
ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for…
- Conditions
- Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor
- Trial name
- START-TKI (NCT05221372)
- Where
- Netherlands
- Volunteers
- 1,300 people
- Sponsor
- Erasmus Medical Center
Non-small Cell Lung Cancer (NSCLC)
Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
This study is a national multicenter real-world investigation aimed at evaluating the real-world effectiveness and safety of Iruplinalkib in the treatment of ALK-positive NSCLC in China.
- Trial name
- NCT05991895
- Testing
- Iruplinalkib
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Jinming Yu
Lung Cancer
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00519831
- Testing
- cetuximab, vinflunine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Small Cell Lung Carcinoma
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
The purpose of the study is to evaluate the safety and potential benefit of combination amuvatinib with standard of care chemotherapy treatment (platinum and etoposide) in small cell lung cancer (SCLC) subjects.
- Trial name
- ESCAPE (NCT01357395)
- Testing
- Amuvatinib
- Where
- 12 sites in United States, Poland
- Volunteers
- 23 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitors.
- Trial name
- NCT01449357
- Testing
- zalutumumab
- Sponsor
- Genmab
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease…
- Trial name
- NCT00556712
- Testing
- erlotinib [Tarceva]
- Where
- 133 sites in Australia, Austria and 26 more
- Volunteers
- 889 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.